Experimental Drug Doubles Lung Cancer Survival
The results of the third-phase trial of the "Biontek" medication demonstrated unprecedented effectiveness in treating one of the most aggressive types of lung cancer, thereby enhancing the prospects of providing a new and effective treatment for patients with this form of cancer.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading